AMAG Pharmaceuticals Company Profile (NASDAQ:AMAG)

AMAG Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMAG."

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) released its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.58) by $0.18. The company had revenue of $158.39 million for the quarter, compared to analysts' expectations of $158.83 million. AMAG Pharmaceuticals had a negative net margin of 7.58% and a negative return on equity of 4.81%. The business's revenue was up 24.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.45 EPS. View AMAG Pharmaceuticals' Earnings History.

AMAG Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for AMAG Pharmaceuticals.

13 brokerages have issued 12 month price targets for AMAG Pharmaceuticals' shares. Their forecasts range from $20.00 to $45.00. On average, they expect AMAG Pharmaceuticals' stock price to reach $28.45 in the next year. View Analyst Ratings for AMAG Pharmaceuticals.

Here are some recent quotes from research analysts about AMAG Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "AMAG has been pursuing strategic acquisitions and deals to boost its portfolio and pipeline. The company is making its investments in the launch of Intrarosa, expansion of the label for Feraheme, development work to support the bremelanotide NDA and expected approval and launch of the Makena subcutaneous auto-injector (SQ) . In June 2017, the FDA accepted the sNDA for the Makena subcutaneous auto-injector. The agency has established a Prescription Drug User Fee Act (PDUFA) target action date of Feb 14, 2018. AMAG is focused on expanding the Makena’s label further in a bid to increase its market share. AMAG’s shares have underperformed the Medical-Biomedical/Genetics industry year to date. Estimates have remained mostly stable lately ahead of the Q2 results. AMAG has a negative record of earnings surprises in the recent quarters." (7/26/2017)
• 2. Cantor Fitzgerald analysts commented, "AMAG announced the commercial launch of Intrarosa (DHEA vaginal insert) as a treatment for moderate to severe dyspareunia associated with vulvar vaginal atrophy (VVA)." (7/24/2017)
• 3. Jefferies Group LLC analysts commented, "No surprise vs. pre-announced 4Q16 results on 1/9/17. Another acquisition of women's health product Intrarosa also fails to excite investors (following Rekynda on 1/9/17). Given ongoing concerns, near-term we view limited upside; medium/long-term share price recovery would likely be driven by timely approval/successful launch of Makena 3.0 & strong Intrarosa uptake providing confidence in its commercial potential, which may not be materialized until ~2018." (2/15/2017)
• 4. Guggenheim analysts commented, "Despite near-term setbacks, we continue to believe patience will be rewarded for AMAG investors with a longer-term horizon. However we are lowering our price target to $28 from $42. Our PT reduction is driven by lowered expectations for Makena life cycle extension. We believe Makena Sub-Q will face a challenging reimbursement environment, if approved, given the pain and Cmax PK data released this morning and expect generics to capture the majority of the market from '18+. Longer term stock price appreciation could be driven by Feraheme label expansion, CBR durability, Business Development, and Rekynda keep us positive." (2/2/2017)

AMAG Pharmaceuticals saw a decrease in short interest in the month of August. As of August 15th, there was short interest totalling 8,685,429 shares, a decrease of 15.6% from the July 31st total of 10,296,798 shares. Based on an average trading volume of 763,177 shares, the short-interest ratio is presently 11.4 days. Currently, 25.3% of the shares of the company are sold short.

Some companies that are related to AMAG Pharmaceuticals include Amphastar Pharmaceuticals (AMPH), Lannett Co (LCI), SciClone Pharmaceuticals (SCLN), Corium International (CORI), Teligent (TLGT), Tetraphase Pharmaceuticals (TTPH), Aceto Corporation (ACET), Aquinox Pharmaceuticals (AQXP), Collegium Pharmaceutical (COLL), Neos Therapeutics (NEOS), Allergy Therapeutics plc (AGY), Adamis Pharmaceuticals Corporation (ADMP), BioDelivery Sciences International (BDSI), Marinus Pharmaceuticals (MRNS), Female Health Company (The) (VERU), Aralez Pharmaceuticals (ARLZ), Diurnal Group PLC (DNL) and BioLife Solutions (BLFS).

AMAG Pharmaceuticals' management team includes the folowing people:

• Gino Santini, Independent Chairman of the Board
• William K. Heiden, President, Chief Executive Officer, Director
• Edward Myles CPA, Chief Financial Officer, Senior Vice President - Finance, Treasurer
• Nathan McBride, Senior Vice President - Innovation Architects, Chief Information Officer
• Joseph D. Vittiglio, Senior Vice President - Legal Affairs, Technical Operations and Quality, General Counsel, Secretary
• Tony Casciano, Senior Vice President of Sales and Marketing - Hematology and Oncology business
• Paul Williams, Senior Vice President - Sales and Marketing, Women’s Health
• Elizabeth Bolgiano, Senior Vice President of Human Resources
• Julie Krop M.D., Chief Medical Officer and Senior Vice President - Clinical Development and Regulatory Affairs
• Scott T. McMillan Ph.D., Senior Vice President - Quality and Technical Operations

AMAG Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Palo Alto Investors LLC (9.48%), Vanguard Group Inc. (8.58%), State Street Corp (7.91%), LSV Asset Management (4.79%), Acadian Asset Management LLC (3.49%) and Dimensional Fund Advisors LP (3.47%). Company insiders that own AMAG Pharmaceuticals stock include John A Fallon, Joseph Vittiglio, Julie Krop and William K Heiden. View Institutional Ownership Trends for AMAG Pharmaceuticals.

AMAG Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Numeric Investors LLC, Bank of New York Mellon Corp, Thrivent Financial For Lutherans, Vanguard Group Inc., OxFORD Asset Management LLP, Goldman Sachs Group Inc., Alliancebernstein L.P. and Fox Run Management L.L.C.. Company insiders that have sold AMAG Pharmaceuticals stock in the last year include Joseph Vittiglio and Julie Krop. View Insider Buying and Selling for AMAG Pharmaceuticals.

AMAG Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Robeco Institutional Asset Management B.V., State Street Corp, Prudential Financial Inc., Dimensional Fund Advisors LP, Gotham Asset Management LLC, Eii Capital Management Inc., Voya Investment Management LLC and Chicago Equity Partners LLC. View Insider Buying and Selling for AMAG Pharmaceuticals.

Shares of AMAG Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of AMAG Pharmaceuticals stock can currently be purchased for approximately $18.20.